Sagittide Therapeutics

Sagittide Therapeutics is a preclinical-stage biotechnology company specializing in the discovery and development of novel cyclic peptides and peptidomimetics for oncology and diagnostic applications. Utilizing its proprietary automated, high-throughput phage display platform, the company designs highly stable single and double cyclic peptides with picomolar to nanomolar affinities. Sagittide's pipeline includes SAG602, a MUC1-C-targeted peptidomimetic-near-infrared (NIR) conjugate for fluorescence-guided cancer surgery, and SAT49 (also known as SAR49), a gallium-68-labeled prostatic acid phosphatase (ACP3)-targeted peptidomimetic for PET imaging of prostate cancer. The company is backed by Nanjing King-Friend Biochemical Pharmaceutical and operates research facilities in Nanjing, China, and Singapore.